Recruiting

Observational Study

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT07030686

Conditions

Survivorship

Recurrent

Recurrence

Cancer

Remission

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Exercise

Study Details

Brief summary:

This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.

Conditions

Survivorship

Recurrent

Recurrence

Cancer

Remission

Study ID

NCT07030686

Start date

Mar 19, 2020

Status verified date

Aug, 2026

Completion date

Mar 19, 2027

Anticipated

Primary completion date

Mar 19, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

Target trial (ideal RCT)

  • Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).
  • Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \[i.e., reporting <10 metabolic equivalent-hours per week (MET-h/week)\]. Patients completing an additional exercise survey between th and baseline are excluded.
  • No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment
  • Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.
  • Undergoing surveillance in the Cancer Survivorship Program at MSK

Emulation using observational data

  • Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.
  • Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).
  • Non-exercising (i.e., reporting <5 MET-h/week) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).
  • Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.
  • No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.
  • Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.

Study Design

Enrollment

61100 participants

Anticipated

Interventions and Outcome Measures

Arms

Arm 1: Usual Care

Arm 2: Exercise

Interventions

Exercise

Exercise following completion of active treatment for the primary index cancer

Primary outcome measure

  • Distant disease-free survival (DDFS) [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Jessica Scott, PhD

646-888-8093scottj1@mskcc.org

Chaya Moskowitz, PhD

646-227-3607moskowc1@MSKCC.ORG

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Jessica Scott, PhD

646-888-8093

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Sep 1, 2026

Last verified

Aug, 2026

Keywords

  • Survivorship
  • Exercise
  • cancer survivor
  • adult cancer survivor
  • no evidence of disease
  • 20-101
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-09-01.